Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice.
Respiratory syncytial virus (RSV) is a high priority target for vaccine development. One concern in RSV vaccine development is that a non-live virus vaccine would predispose for enhanced disease similar to that seen with the formalin inactivated RSV (FI-RSV) vaccine. Since a mAb specific to RSV G pr...
Main Authors: | Gertrud U Rey, Congrong Miao, Hayat Caidi, Suvang U Trivedi, Jennifer L Harcourt, Ralph A Tripp, Larry J Anderson, Lia M Haynes |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3871585?pdf=render |
Similar Items
-
Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice.
by: Hayat Caidi, et al.
Published: (2012-01-01) -
Effects of formalin-inactivated respiratory syncytial virus (FI-RSV) in the perinatal lamb model of RSV.
by: Rachel J Derscheid, et al.
Published: (2013-01-01) -
Pathobiology of Respiratory Syncytial Virus (RSV)
by: Ralph A. Tripp, et al.
Published: (2020-07-01) -
Emergency Department Septic Screening in Respiratory Syncytial Virus (RSV) and Non-RSV Bronchiolitis
by: Chee, Chris, et al.
Published: (2010-02-01) -
Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B.
by: Anne M Hause, et al.
Published: (2017-01-01)